InvestSMART

Telix Pharmaceuticals Limited (ASX:TLX)

ALERT: Price-sensitive ASX Announcement for TLX
Current share price for TLX : $15.650 -1.19 (-7.07%)+
Announcement
Release
20 Aug 2026 8:40AM
Price at Release
$16.840
Full Release
download
Summary
Telix Pharmaceuticals Limited has reported significant financial growth for the half-year ended June 30, 2026. Revenue rose by 22% to $477.3 million, driven primarily by its Precision Medicine segment. The company achieved a positive Adjusted EBITDA of $51.9 million and an operational profit increase of 346%. Furthermore, Telix reversed its previous loss with a profit of $38.3 million, attributing to a total comprehensive income of $9.458 million. Key financial actions included the issuance of $600 million in convertible notes. The company also saw increases in R&D and general administration costs, while its net assets grew to $487.7 million.
Key Points
  • Telix Pharmaceuticals Limited reported a 22% increase in revenue to $477.3 million for the period ended June 30, 2026.
  • The Precision Medicine segment was the main contributor to the revenue growth, generating $388.6 million.
  • The company achieved a positive Adjusted EBITDA of $51.9 million.
  • Operational profit increased by 346% compared to the previous period.
  • Profit for the period attributable to owners was $38.3 million, reversing a previous loss.
  • Total comprehensive income for the period was $9.458 million.
  • The company issued $600 million worth of 1.50% convertible notes due 2031.
  • Research and development costs rose by 52% to $123.8 million.
  • General and administration costs increased slightly by 2% to $48.7 million.
  • Net assets increased to $487.7 million from $415.4 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.